Janssen receives chmp positive opinion for guselkumab recommending approval for the treatment of moderate to severe plaque psoriasis in the european union

Pending approval, guselkumab will be the first biologic that selectively blocks interleukin (IL)-23
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news